Skip to main content

Chronix, U of Calgary to Develop Mad Cow Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Chronix Biomedical and the University of Calgary have partnered to develop a commercial version of a serum DNA-based test for early detection of bovine spongiform encephalopathy (BSE), commonly called mad cow disease, Chronix said today.

Chronix is developing a diagnostic, monitoring, and management testing technology that can identify and analyze DNA fragments circulating in the bloodstream. The firm published data in 2009 showing that these techniques could be used to detect BSE in cattle before disease symptoms show.

The BSE assay development project is supported by a grant from Genome Canada and the Alberta Livestock and Meat Agency. Chronix said that it expects to begin offering the BSE testing service to the cattle industry once the commercial test is finalized and validated.

The BSE test will be the first commercial application of the Chronix technology, which is generally being developed for detecting and monitoring human diseases such as cancer and chronic conditions.

"This effort is critically important because the risk of introducing BSE into the food chain continues to worry consumers and hinder international trade," University of Calgary Professor Christoph Sensen said in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.